The effect of HIV infection on longitudinal lung function decline among IDUs: a prospective cohort

Drummond, Michael Bradleya; Merlo, Christian A.a; Astemborski, Jacquieb; Kalmin, Mariah M.c; Kisalu, Annamarieb; Mcdyer, John F.d; Mehta, Shruti H.b; Brown, Robert H.a,e; Wise, Robert A.a; Kirk, Gregory D.a,b

doi: 10.1097/QAD.0b013e32835e395d
Epidemiology and Social

Objective: As survival with HIV infection improves, HIV-infected individuals appear to be susceptible to development of chronic diseases, including restrictive and obstructive lung diseases. We sought to determine the independent association of HIV infection on lung function decline.

Design: Longitudinal analysis of the AIDS Linked to the Intravenous Experience study, an observational cohort of current and former IDUs.

Methods: Generalized estimating equations were used to determine the effects of markers of HIV infection on adjusted annual change in forced expiratory volume in one second (FEV1) and forced vital capacity (FVC).

Results: A total of 1064 participants contributed 4555 spirometry measurements over a median follow-up time of 2.75 years. The mean age of the cohort was 48 years; nearly, two-thirds were men and 85% current smokers. After adjustment, the overall annual decline of FEV1 and FVC between HIV-infected and uninfected persons did not differ. However, there was a 76 ml/year greater rate of decline in FEV1 and 86 ml/year greater rate of decline in FVC among HIV-infected participants with viral load more than 75 000 copies/ml compared with HIV-uninfected individuals (P < 0.01). Similarly, HIV-infected individuals with CD4 cell count less than 100 cells/μl had a 57 ml/year more rapid decline in FEV1 and 86 ml/year more rapid decline in FVC than HIV-uninfected participants (P = 0.018 and P = 0.001, respectively).

Conclusion: Markers of poorly controlled HIV disease are independently associated with accelerated annual lung function decline, with decrements in both FEV1 and FVC. These findings highlight the need for optimized HIV antiretroviral therapy in addition to smoking cessation among HIV-infected individuals with tobacco dependence.

aDepartment of Medicine, School of Medicine, Johns Hopkins University

bDepartment of Epidemiology, Bloomberg School of Public Health, Johns Hopkins University, Baltimore, Maryland

cDepartment of Epidemiology, School of Public Health and Health Services, George Washington University, Washington, District of Columbia

dDepartment of Medicine, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania

eDepartment of Environmental Health Sciences, Bloomberg School of Public Health, Johns Hopkins University, Baltimore, Maryland, USA.

Correspondence to Michael Bradley Drummond, MD, MHS, Division of Pulmonary and Critical Care Medicine, 5501 Hopkins Bayview Circle, JHAAC 4B.70, Baltimore, MD 21224, USA. Tel: +1 410 550 6431; fax: +1 410 550 8050; e-mail: mdrummo3@jhmi.edu

Received 17 October, 2012

Revised 11 December, 2012

Accepted 21 December, 2012

Supplemental digital content is available for this article. Direct URL citations appear in the printed text and are provided in the HTML and PDF versions of this article on the journal's Website (http://www.AIDSonline.com).

© 2013 Lippincott Williams & Wilkins, Inc.